HDAC inhibitors in kidney development and disease.

Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA
Pediatr Nephrol. 2013 28 (10): 1909-21

PMID: 23052657 · PMCID: PMC3751322 · DOI:10.1007/s00467-012-2320-8

The discovery that histone deacetylase inhibitors (HDACis) can attenuate acute kidney injury (AKI)-mediated damage and reduce fibrosis in kidney disease models has opened the possibility of utilizing HDACis as therapeutics for renal injury. Studies to date have made it abundantly clear that HDACi treatment results in a plethora of molecular changes, which are not always linked to histone acetylation, and that there is an essential need to understand the specific target(s) of any HDACi of interest. New lines of investigation are beginning to delve more deeply into target identification of specific HDACis and to address the relative toxicity of different HDACi classes. This review will focus on the utilization of HDACis during kidney organogenesis, injury, and disease, as well as on the development of these compounds as therapeutics.

MeSH Terms (8)

Animals Histone Deacetylase Inhibitors Histone Deacetylases Humans Kidney Kidney Diseases Organogenesis Treatment Outcome

Connections (3)

This publication is referenced by other Labnodes entities: